BRPI0918739A2 - anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição. - Google Patents

anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição.

Info

Publication number
BRPI0918739A2
BRPI0918739A2 BRPI0918739A BRPI0918739A BRPI0918739A2 BR PI0918739 A2 BRPI0918739 A2 BR PI0918739A2 BR PI0918739 A BRPI0918739 A BR PI0918739A BR PI0918739 A BRPI0918739 A BR PI0918739A BR PI0918739 A2 BRPI0918739 A2 BR PI0918739A2
Authority
BR
Brazil
Prior art keywords
composition
antibody
animals
nucleic acid
acid molecule
Prior art date
Application number
BRPI0918739A
Other languages
English (en)
Inventor
Jenkins David
Singh Kang Jaspal
Laing Naomi
Michaud Neil
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BRPI0918739A2 publication Critical patent/BRPI0918739A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
BRPI0918739A 2008-09-19 2009-09-18 anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição. BRPI0918739A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9869708P 2008-09-19 2008-09-19
US11955808P 2008-12-03 2008-12-03
PCT/GB2009/051218 WO2010032061A1 (en) 2008-09-19 2009-09-18 Antibodies against sonic hedgehog homolog and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0918739A2 true BRPI0918739A2 (pt) 2017-09-26

Family

ID=41237627

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918739A BRPI0918739A2 (pt) 2008-09-19 2009-09-18 anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição.

Country Status (10)

Country Link
US (2) US8207306B2 (pt)
EP (1) EP2344535A1 (pt)
JP (1) JP2012502967A (pt)
KR (1) KR20110059755A (pt)
CN (1) CN102203135A (pt)
AU (1) AU2009294416B2 (pt)
BR (1) BRPI0918739A2 (pt)
CA (1) CA2734330A1 (pt)
MX (1) MX2011002838A (pt)
WO (1) WO2010032061A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207306B2 (en) * 2008-09-19 2012-06-26 Medimmune, Llc Targeted binding agents directed to sonic hedgehog homolog and uses thereof
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
NZ605260A (en) * 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
EP2806948B1 (en) * 2012-01-27 2020-01-15 New York University Method for enhancing remyelination using gli1 inhibitors
US20150272970A1 (en) * 2012-09-07 2015-10-01 Carlos Cordon-Cardo Targeting chemotherapy agent resistance in cancer
JP2016530243A (ja) * 2013-07-18 2016-09-29 アン アンド ロバート エイチ．ルリー チルドレンズ ホスピタル オブ シカゴ 神経管欠損症を検出及び治療する組成物及び方法
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
EP3088517B1 (en) 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN109071665B (zh) * 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
US11479601B2 (en) * 2016-06-29 2022-10-25 The Regents Of The University Of California Antibodies specific to Sonic Hedgehog and method of use thereof
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
JOP20200157A1 (ar) 2017-12-22 2022-10-30 Teneobio Inc أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
WO2019164891A1 (en) * 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
UY38748A (es) 2019-06-14 2021-01-29 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN113025614B (zh) * 2021-03-22 2022-08-19 四川大学华西医院 一种胶质瘤诊断和/或预后评估标志物及其应用
WO2023152567A2 (en) * 2022-02-14 2023-08-17 The Hong Kong University Of Science And Technology Disruption of sonic hedgehog-surf4 interaction for cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207306B2 (en) * 2008-09-19 2012-06-26 Medimmune, Llc Targeted binding agents directed to sonic hedgehog homolog and uses thereof

Also Published As

Publication number Publication date
WO2010032061A1 (en) 2010-03-25
JP2012502967A (ja) 2012-02-02
KR20110059755A (ko) 2011-06-03
US8569459B2 (en) 2013-10-29
AU2009294416A1 (en) 2010-03-25
CN102203135A (zh) 2011-09-28
MX2011002838A (es) 2011-07-29
AU2009294416B2 (en) 2014-05-22
CA2734330A1 (en) 2010-03-25
US20120328625A1 (en) 2012-12-27
US8207306B2 (en) 2012-06-26
EP2344535A1 (en) 2011-07-20
US20100196388A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
BRPI0918739A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição.
BRPI0918555A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
EA201000146A1 (ru) Связующее майларда на основе гидроксимонокарбоновой кислоты
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0818287A2 (pt) células dendríticas manipuladas e usos para o tratamento do câncer.
BRPI0811755A2 (pt) Amplificação específica de senquência de dna específicas de tumor.
BRPI0819714A2 (pt) Formulações de proteína e métodos de produção das mesmas.
BRPI0906099A2 (pt) "método de tratamento do câncer em um indivíduo"
BRPI0714876A2 (pt) glucanases, ácidos nucleicos codificando as mesmas e métodos para fabricar e usar as mesmas.
IT1391619B1 (it) Metodo per l'individuazione, selezione e analisi di cellule tumorali
BRPI0921122A2 (pt) sistema de terapia de próstata.
BRPI0921422A2 (pt) sistema de terapia de próstata.
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0916121A2 (pt) "métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição"
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BR112013007229A2 (pt) ''composição,mistura e processo''.
BRPI0919316A2 (pt) sistema comestico ou dermatologico, e, metodo para tratar cosmeticamente pele ou cabelo
BRPI0905761A2 (pt) Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit
BRPI0913300A2 (pt) composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica.
BRPI0822218A2 (pt) Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las.
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]